Tano et al., evaluated the relationship between the expression ratio of mRNAs for the antiapoptotic protein Bcl-2 and the proapoptotic protein Bax (the Bcl-2/Bax ratio) and clinical outcomes in patients with HNSCC; wherein DFS of patients with Bcl-2/Bax ratios ≥ 1.2 was noted to be longer than that of patients with Bcl-2/Bax ratios < 1.2 (67). This evidence concerns the gene BCL2 and head and neck squamous cell carcinoma.